Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2014

View Archived Issues

Mymetics to manufacture Imugene's HER-Vaxx cancer immunotherapy

Medigene completes capital increase to fund cancer immunotherapy programs

Immatics biotechnologies receives final tranche of series D financing

C2N expands partnership with WUSM for Alzheimer's blood test

La Jolla Pharmaceutical's LJPC-1010 shows promise in preclinical model of NASH

Lilly discloses new anti-BMP-6 MAbs

Daiichi Sankyo to begin several trials of DS-5565 for pain associated with fibromyalgia

Novartis patents new modified IGF-I polypeptides

New disulfide-linked multivalent multi-function proteins divulged by Roche

Merck & Co. synthesizes novel glucokinase activators

Novel gamma-secretase modulators synthesized by Janssen Pharmaceutica

CSF proteins as potential markers of pediatric CNS tumors

Novel CFTR channel inhibitors patented by Novartis

Researchers from Lexicon present promising data for LX-4211 in humans and mice

Actinium Pharmaceuticals begins development of new actinium-225-labeled antibody construct

Researchers in France divulge new agents for mycobacterial infections

FDA lifts partial clinical hold on CTP-354

SUVN-A60203 counteracts cognitive defects associated with neuropathic pain

Epirus Biopharmaceuticals and Zalicus complete merger

Nintedanib receives breakthrough therapy designation for idiopathic pulmonary fibrosis

InnoPharma acquired by Pfizer

Isavuconazole receives another QIDP designation from FDA

BioLineRx reports data from phase I/II study of BL-7010 in celiac disease

FDA approves Ruconest for acute angioedema attacks

Lorus Therapeutics proposes name change

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...